The role of brevican in glioma: Promoting tumor cell motility in vitro and in vivo

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Lu, Renquan ^a,b   Wu, Chengsheng ^a   Guo, Lin ^b   Liu, Yingchao ^c   Mo, Wei ^a   Wang, Huijie ^b   Ding, Jianbo ^d   Wong, Eric T ^e   Yu, Min ^a  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^d FUDAN UNIVERSITY   (China)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Astrocytoma; Brevican; Glioma; Motility; Tumorigenicity

Indexed keywords

BREVICAN; DNA; SHORT HAIRPIN DNA; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CELL ADHESION; CELL DIFFERENTIATION; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL TRANSPORT; CONTROLLED STUDY; CYTOLOGY; DOWN REGULATION; FEMALE; GENE SILENCING; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MOLECULAR MECHANICS; PROTEIN EXPRESSION; TUMOR CELL; TUMOR GROWTH;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; BLOTTING, WESTERN; BRAIN NEOPLASMS; BREVICAN; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; YOUNG ADULT;

EID: 84871171246     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-607     Document Type: Article

References (31)

1. Bolteus AJ, Berens ME, Pilkington GJ. Migration and invasion in brain neoplasms. Curr Neurol Neurosci Rep 2001, 1(3):225-232. 10.1007/s11910-001-0022-x, 11898522.
2. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008, 70(10):779-787. 10.1212/01.wnl.0000304121.57857.38, 18316689.
3. Iwamoto FM, Abrey LE, Beal K, Gutin PH, Rosenblum MK, Reuter VE, DeAngelis LM, Lassman AB. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 2009, 73(15):1200-1206. 10.1212/WNL.0b013e3181bc0184, 2839807, 19822869.
4. Rauch U, Meyer H, Brakebusch C, Seidenbecher C, Gundelfinger ED, Beier DR, Fassler R. Sequence and chromosomal localization of the mouse brevican gene. Genomics 1997, 44(1):15-21. 10.1006/geno.1997.4853, 9286696.
5. Ruoslahti E. Brain extracellular matrix. Glycobiology 1996, 6(5):489-492. 10.1093/glycob/6.5.489, 8877368.
6. Yamaguchi Y. Lecticans: organizers of the brain extracellular matrix. Cell Mol Life Sci 2000, 57(2):276-289. 10.1007/PL00000690, 10766023.
7. Gary SC, Zerillo CA, Chiang VL, Gaw JU, Gray G, Hockfield S. cDNA cloning, chromosomal localization, and expression analysis of human BEHAB/brevican, a brain specific proteoglycan regulated during cortical development and in glioma. Gene 2000, 256(1-2):139-147.
8. Jaworski DM, Kelly GM, Piepmeier JM, Hockfield S. BEHAB (brain enriched hyaluronan binding) is expressed in surgical samples of glioma and in intracranial grafts of invasive glioma cell lines. Cancer Res 1996, 56(10):2293-2298.
9. Zhang H, Kelly G, Zerillo C, Jaworski DM, Hockfield S. Expression of a cleaved brain-specific extracellular matrix protein mediates glioma cell invasion In vivo. J Neurosci 1998, 18(7):2370-2376.
10. Viapiano MS, Bi WL, Piepmeier J, Hockfield S, Matthews RT. Novel tumor-specific isoforms of BEHAB/brevican identified in human malignant gliomas. Cancer Res 2005, 65(15):6726-6733. 10.1158/0008-5472.CAN-05-0585, 16061654.
11. Lu R, Sun M, Feng J, Gao X, Guo L. Myofibrillogenesis regulator 1 (MR-1) is a novel biomarker and potential therapeutic target for human ovarian cancer. BMC Cancer 2011, 11:270. 10.1186/1471-2407-11-270, 3132198, 21702971.
12. Choudhury KR, Yagle KJ, Swanson PE, Krohn KA, Rajendran JG. A Robust Automated Measure of Average Antibody Staining in Immunohistochemistry Images. J Histochem Cytochem 2010, 58(2):95-107. 10.1369/jhc.2009.953554, 2803710, 19687472.
13. LU RQ Wu HJ, Guo L. Construction, Expression of HE4 Fusion Protein and its identification. Chin J Lab Diag 2010, 14:17-19.
14. Nutt CL, Matthews RT, Hockfield S. Glial tumor invasion: a role for the upregulation and cleavage of BEHAB/brevican. Neuroscientist 2001, 7(2):113-122. 10.1177/107385840100700206, 11496922.
15. Hu B, Kong LL, Matthews RT, Viapiano MS. The proteoglycan brevican binds to fibronectin after proteolytic cleavage and promotes glioma cell motility. J Biol Chem 2008, 283(36):24848-24859. 10.1074/jbc.M801433200, 3259830, 18611854.
16. Viapiano MS, Hockfield S, Matthews RT. BEHAB/brevican requires ADAMTS-mediated proteolytic cleavage to promote glioma invasion. J Neurooncol 2008, 88(3):261-272. 10.1007/s11060-008-9575-8, 18398576.
17. Candolfi M, Curtin JF, Nichols WS, Muhammad AG, King GD, Pluhar GE, McNiel EA, Ohlfest JR, Freese AB, Moore PF, et al. Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J Neurooncol 2007, 85(2):133-148. 10.1007/s11060-007-9400-9, 2384236, 17874037.
18. Goldbrunner RH, Bernstein JJ, Tonn JC. Cell-extracellular matrix interaction in glioma invasion. Acta Neurochir (Wien) 1999, 141(3):295-305. discussion 304-295.
19. Jaworski DM, Kelly GM, Hockfield S. BEHAB, a new member of the proteoglycan tandem repeat family of hyaluronan-binding proteins that is restricted to the brain. J Cell Biol 1994, 125(2):495-509. 10.1083/jcb.125.2.495, 2120027, 7512973.
20. Seidenbecher CI, Richter K, Rauch U, Fassler R, Garner CC, Gundelfinger ED. Brevican, a chondroitin sulfate proteoglycan of rat brain, occurs as secreted and cell surface glycosylphosphatidylinositol-anchored isoforms. J Biol Chem 1995, 270(45):27206-27212. 10.1074/jbc.270.45.27206, 7592978.
21. Yamada H, Watanabe K, Shimonaka M, Yamaguchi Y. Molecular cloning of brevican, a novel brain proteoglycan of the aggrecan/versican family. J Biol Chem 1994, 269(13):10119-10126.
22. Viapiano MS, Matthews RT, Hockfield S. A novel membrane-associated glycovariant of BEHAB/brevican is up-regulated during rat brain development and in a rat model of invasive glioma. J Biol Chem 2003, 278(35):33239-33247. 10.1074/jbc.M303480200, 12799382.
23. Wang R, Clark RA, Mosher DF, Ren XD. Fibronectin's central cell-binding domain supports focal adhesion formation and Rho signal transduction. J Biol Chem 2005, 280(31):28803-28810. 10.1074/jbc.M501421200, 15964831.
24. Yamaguchi Y. Brevican: a major proteoglycan in adult brain. Perspect Dev Neurobiol 1996, 3(4):307-317.
25. Lettau I, Hattermann K, Held-Feindt J, Brauer R, Sedlacek R, Mentlein R. Matrix metalloproteinase-19 is highly expressed in astroglial tumors and promotes invasion of glioma cells. J Neuropathol Exp Neurol 2010, 69(3):215-223. 10.1097/NEN.0b013e3181ce9f67, 20142769.
26. Louis DN. Molecular pathology of malignant gliomas. Annu Rev Pathol 2006, 1:97-117. 10.1146/annurev.pathol.1.110304.100043, 18039109.
27. Nutt CL, Zerillo CA, Kelly GM, Hockfield S. Brain enriched hyaluronan binding (BEHAB)/brevican increases aggressiveness of CNS-1 gliomas in Lewis rats. Cancer Res 2001, 61(19):7056-7059.
28. Stanton H, Melrose J, Little CB, Fosang AJ. Proteoglycan degradation by the ADAMTS family of proteinases. Biochim Biophys Acta 1812, 12:1616-1629.
29. Pilkington GJ. The paradox of neoplastic glial cell invasion of the brain and apparent metastatic failure. Anticancer Res 1997, 17(6B):4103-4105.
30. Subramanian A, Harris A, Piggott K, Shieff C, Bradford R. Metastasis to and from the central nervous system-the 'relatively protected site'. Lancet Oncol 2002, 3(8):498-507. 10.1016/S1470-2045(02)00819-7, 12147436.
31. Cattaruzza S, Perris R. Proteoglycan control of cell movement during would healing and cancer spreading. Matrix Biol 2005, 24(6):400-417. 10.1016/j.matbio.2005.06.005, 16055321.